This content is only available within our institutional offering.
28 Apr 2020
LIBERUM: Morning Comment
Oxford BioMedica plc (OXB:LON), 326 | Plus500 Ltd. (PLUS:LON), 2,237 | XPS Pensions Group Plc (XPS:LON), 252 | Ricardo plc (RCDO:LON), 501 | Novartis AG (NOVN:SWX), 0 | Bayer AG (BAYN:ETR), 0 | Symrise AG (SY1:ETR), 0 | Coca-Cola Europacific Partners plc (CCEP:NAS), 0 | Travis Perkins plc (TPK:LON), 830 | Marks and Spencer Group plc (MKS:LON), 266 | Weir Group PLC (WEIR:LON), 2,099 | Burford Capital Limited (BUR:LON), 0 | MITIE Group PLC (MTO:LON), 120 | Sylvania Platinum Ltd. (SLP:LON), 69.0
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
LIBERUM: Morning Comment
Oxford BioMedica plc (OXB:LON), 326 | Plus500 Ltd. (PLUS:LON), 2,237 | XPS Pensions Group Plc (XPS:LON), 252 | Ricardo plc (RCDO:LON), 501 | Novartis AG (NOVN:SWX), 0 | Bayer AG (BAYN:ETR), 0 | Symrise AG (SY1:ETR), 0 | Coca-Cola Europacific Partners plc (CCEP:NAS), 0 | Travis Perkins plc (TPK:LON), 830 | Marks and Spencer Group plc (MKS:LON), 266 | Weir Group PLC (WEIR:LON), 2,099 | Burford Capital Limited (BUR:LON), 0 | MITIE Group PLC (MTO:LON), 120 | Sylvania Platinum Ltd. (SLP:LON), 69.0
- Published:
28 Apr 2020 -
Author:
Liberum Research Team -
Pages:
7